Bioventure FZ-LLC and AJA Pharmaceuticals, a subsidiary of Saudi Chemical Company Holding (SCCH) signed a Memorandum of Understanding (MoU) to strengthen the existing strategic partnership between the two institutions.
The collaboration will focus on diabetes, oncology and biosimilars, therapeutic categories that are forecasted to be among the largest and fastest-growing within the global pharma sector over the coming years.
The extension of the long-standing strategic partnership between Bioventure and AJA involves a variety of delivery forms, including complex to develop formulations.
Bioventure continues to strengthen its position in the region, providing the healthcare community and their patients with high-quality, accessible and affordable treatment.
Commenting on the agreement, Eng. Thamer Al-Muhid, GCEO of SCCH and MD, said: “(SCCH) aspires to develop its manufacturing arm in the pharma sector, AJA Pharma, through such investment which will contribute to strengthening its position as a Saudi Pharmaceutical manufacturer in the field of Oncology, Diabetes and Specialty products, to serve and meet community needs.”
Also, Ashraf Radwan, CEO of GlobalOne Healthcare, said: “Bioventure is committed to improving access to quality healthcare for patients in the Middle East, and this MoU with AJA Pharma marks a significant step towards achieving that goal. By expanding our licensing and supply capabilities, we can bring a wider range of innovative, effective treatments to the people who need them most. I am thrilled to be working with AJA Pharma to bring these solutions to patients in the Middle East and make a meaningful difference in their lives”.